The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pinpoint Cognitive Dysfunction in Patients with Lupus

Pinpoint Cognitive Dysfunction in Patients with Lupus

April 6, 2012 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF

CHICAGO—Cognitive impairment. Memory loss. Headaches. Psychosis. These symptoms are not uncommon in patients with systemic lupus erythematosus (SLE). In fact, “over 80% of SLE patients experience some type of neurologic manifestation during their disease course,” said Robin L. Brey, MD, professor and chair of neurology at the University of Texas Health Science Center at San Antonio.

You Might Also Like
  • Lupus & Cognitive Dysfunction: No Apparent Link to Inflammation
  • Physical & Cognitive Function in SLE Patients
  • How Depression Affects the Cognitive Profile of Fibromyalgia Patients
Explore This Issue
April 2012
Also By This Author
  • Where Will Kinase Inhibitors Fit into the RA Treatment Mix?

The challenge for rheumatologists and other clinicians lies in appropriately diagnosing any cognitive dysfunctions that accompany lupus and better understanding the causes and risk factors of those dysfunctions, Dr. Brey said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Cognitive Function in SLE” was the focus of a talk by Dr. Brey at the 2011 ACR/ARHP Annual Scientific Meeting in November. [Editor’s note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.]

Look at the Numbers

Studies show varying percentages of SLE patients who experience cognitive dysfunction and neuropsychiatric symptoms, Dr. Brey said. “If you look at studies that try to estimate a frequency of neurologic manifestations in lupus, it’s all over the place,” she said. However, studies that use neuropsychiatric testing consistently find a higher frequency of cognitive dysfunction, she explained.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Studies conducted with sensitive testing instruments find 69% to 74% of SLE patients experiencing mood disorders and 75% to 80% experiencing cognitive dysfunction, she said.

Contrary to that, a 2007 study found only 12.4% of SLE patients had mood disorders and only 5.4% had cognitive dysfunction.1 “You might ask, ‘Who’s right?’ ” Dr. Brey said. “I’d say both. The [latter] study didn’t use sensitive instruments to look at these factors. I think the answer is somewhere in the middle.”

Research has found that neuropsychiatric damage is the most common domain involved in lupus, followed by renal and ocular domains, noted Dr. Brey. “This is one of the best arguments for paying attention to the nervous system in lupus patients,” she said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

One challenge in pinpointing cognitive dysfunction in potential SLE patients is that these symptoms can manifest in the absence of serologic activity, Dr. Brey said. “It can make it difficult to know if the neurological manifestations are due to lupus or something else. The challenge for those of us taking care of these patients is to try to determine if neurological symptoms are due to lupus or whether they are secondary to other things,” she said.

This becomes even more challenging when you consider that some of the cognitive symptoms, such as headaches, anxiety, and mild depression, are common in the general population. However, studies focusing specifically on neurological symptoms in SLE find headaches, seizures, stroke, and psychosis to be consistently more common, Dr. Brey said.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports, SLE (Lupus) Tagged With: ACR/ARHP Annual Meeting, brain, cognitive dysfunction, Diagnostic Criteria, drug, HYDROXYCHLOROQUINE, Lupus, Research, SLE, Systemic lupus erythematosusIssue: April 2012

You Might Also Like:
  • Lupus & Cognitive Dysfunction: No Apparent Link to Inflammation
  • Physical & Cognitive Function in SLE Patients
  • How Depression Affects the Cognitive Profile of Fibromyalgia Patients
  • Insight into Endothelial Dysfunction in Early SLE Patients without Cardiovascular Disease

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.